ArticleExperimental hematology & oncology2025
Spatial ecostructural modelling of endometrial cancer identifies the key role of CD90 + CD105 + endothelial cells in tumour heterogeneity and predicts disease recurrence.
Article in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrating artificial intelligence and multi-omics data for precision oncology in endometrial cancer: a narrative review.Functional & integrative genomics · 2026Review
- TAMs in the Gynecological Tumor Microenvironment: Insights from Cross-Cancer Studies for Immunotherapy.Cancers · 2026Review
- Matrix stiffness induces CaExperimental hematology & oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundCurrent therapeutic strategies for endometrial cancer are mainly based on aggressive histological types and molecular subtypes. However, ignoring the spatial distribution of immune/stromal cells fails to account for the heterogeneity of the local tumour microenvironment, leading to biased prediction of treatment response. The goal of precision medicine is to delineate the biological characteristics of local functional units based on molecular labelling, which adequately reflects spatially adaptive changes during treatment or metastasis.
methodsSingle-cell resolution analysis of 40 endometrial cancer cases across four molecular subtypes was performed using imaging mass cytometry (IMC) to quantify the frequency, spatial distribution, and intercellular crosstalk of distinct immune and stromal cell populations. These ecosystem-level features were systematically correlated with clinical features and outcomes, including treatment response and survival. We further identified CD90 + clusters as key regulators of macrophage polarization and T-cell infiltration dynamics, with flow cytometry used to validate their functional role in tumour subtype specification and microenvironmental remodelling. Finally, machine learning-based spatial phenotyping was employed to construct molecular subtype-specific signatures and a highly accurate recurrence prediction model for high-risk endometrial cancer.
resultsSingle-cell profiling revealed that CD90 + clusters constitute a critical immunomodulatory component within the tumour microenvironment, demonstrating significant enrichment in macrophage differentiation pathways and serving as key mediators of intercellular signalling networks. Furthermore, computational models integrating functional molecular signatures with cell-cell interaction profiles demonstrated high predictive accuracy for both molecular subtyping and recurrence risk stratification in patients with endometrial carcinoma.
conclusionsOur study establishes a spatial eco-context framework for molecular subtypes of endometrial cancer by integrating single-cell spatial multiomics data. This approach enables high-resolution mapping of tumour-immune-stromal interaction networks and reveals novel targets for personalized therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.